Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVE trial of suPAR-guided early anakinra in COVID-19
2020-001466-11Phase 2Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Apr 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anakinra in coronavirus disease 2019 (COVID-19), viral pneumonia and pulmonary infection, sponsored by Hellenic Institute for the Study of Sepsis. Primary endpoint: Patients without SAIs at day 14. Started Apr 2020; status: completed.
02
Drugs
anakinra
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumoniapulmonary infection
Beyond the preview
Go deeper on 2020-001466-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001466-11.